Evaxion to Present AML Vaccine Data at ASH Meeting
Evaxion A/S announced it will present new target validation data for its off-the-shelf therapeutic vaccine candidate, EVX-04, for acute myeloid leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting and Exposition. The data, which further validate the potential of EVX-04, will be presented in a poster session. EVX-04 utilizes Evaxion's AI-Immunology™ platform to target endogenous retrovirus (ERV) tumor antigens, aiming for broad patient coverage and immediate administration post-diagnosis.
Key Highlights
- Evaxion to present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML).
- Data will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, December 12-15, 2026.
- EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens identified by Evaxion's AI-Immunology™ platform.
- The vaccine is designed for broad patient coverage and is an off-the-shelf product, ready for immediate administration.
- Poster presentation title: Validation of conserved ERV targets encoded by the off-the-shelf EVX-04 DNA vaccine for AML.
- Poster number: 4310, Session: 801. Gene Therapies: Poster II, Date: Sunday, December 13, 2026.
Price Impact
More from EVAX
Evaxion A/S: Phase 2 data show strong immune response from EVX-01 cancer vaccine
Evaxion to Present Positive Phase 2 Data for Cancer Vaccine EVX-01 at SITC
Evaxion's EVX-01 Cancer Vaccine Shows 89% Target Precision, Sustained Response